Skip to main content
TipRanks
Go Ultimate75% OFF

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) AI Stock Analysis

2 Followers
IN:JAGSNPHARM

Jagsonpal Pharmaceuticals Ltd.

(NSE:JAGSNPHARM)

Select Model
Rating:78Outperform
Price Target:INR 263.00▲(21.73% Upside)
Action:reiterated
Date:08/19/26

The overall score is driven primarily by a robust financial profile, combining strong profitability, a very conservative balance sheet, and high‑quality cash generation that support resilience. Technicals add a supportive but not strongly momentum‑driven backdrop, with the stock trading above key moving averages yet showing only moderate near‑term strength. A valuation that leans on growth rather than income slightly tempers the upside, keeping the score in the upper‑mid range rather than at a premium level.

Positive Factors
Low LeverageMinimal leverage gives Jagsonpal substantial financial flexibility and reduces the burden of interest and refinancing obligations. This supports resilience through weaker operating periods while preserving capacity to fund product development, distribution expansion, or other growth initiatives internally.
Negative Factors
Earnings DeclineThe decline in net income despite stronger revenue shows that top-line expansion has not consistently translated into bottom-line growth. Persistent earnings conversion pressure could limit retained capital, weaken returns to shareholders, and make future profitability less predictable.

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) vs. iShares MSCI India ETF (INDA)

-30%-20%-10%0%10%20%IN:JAGSNPHARM+3.86%INDA-5.86%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 11.37B
Dividend Yield
1.84%
Average Volume (3M)
12.96K
Price to Earnings (P/E)
31.9
Beta (1Y)
0.80
Revenue Growth
11.71%
EPS Growth
-26.92%
Country
India
Employees
1,297
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Jagsonpal Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Jagsonpal Pharmaceuticals Limited, an Indian company founded in 1964 and based in New Delhi, specializes in the development and manufacturing of both bulk active pharmaceutical ingredients and diverse medicinal formulations. Its product portfolio spa...

How the Company Makes Money

Jagsonpal Pharmaceuticals primarily makes money by selling pharmaceutical formulations (finished dosage medicines) in the Indian market. Revenue is generated through (1) domestic sales of branded formulations to channel partners such as stockists/dis...

Jagsonpal Pharmaceuticals Ltd. Financial Statement Overview

Summary

Score reflects strong revenue growth over several years, high margins, a conservative low‑debt balance sheet, and consistently positive, well‑aligned operating and free cash flows, offset by recent margin and return moderation and some volatility in growth and cash flows.

Income Statement

78Positive

Balance Sheet

85Very Positive

Cash Flow

82Very Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue3.16B2.87B2.69B2.09B2.37B2.18B
Gross Profit1.45B1.83B1.72B652.59M1.44B1.28B
EBITDA656.32M679.90M510.71M323.46M362.61M284.29M
Net Income451.90M430.82M553.61M224.63M267.21M188.55M
Balance Sheet
Total Assets3.18B3.17B2.78B2.17B1.95B1.68B
Cash, Cash Equivalents and Short-Term Investments1.15B1.06B1.29B1.48B1.15B472.77M
Total Debt92.16M81.65M92.39M89.41M60.01M52.47M
Total Liabilities739.81M405.05M383.10M296.76M360.56M375.99M
Stockholders Equity2.41B2.76B2.40B1.87B1.59B1.31B
Cash Flow
Free Cash Flow0466.64M549.52M349.18M463.37M51.31M
Operating Cash Flow0468.12M553.00M351.66M466.54M55.98M
Investing Cash Flow0-356.49M-451.47M-245.48M-576.71M-257.79M
Financing Cash Flow0-121.49M-116.98M-89.11M-4.57M-175.52M

Jagsonpal Pharmaceuticals Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price216.05

Price Trends

50DMA226.76Negative
100DMA227.20Negative
200DMA207.11Positive

Market Momentum

MACD-2.72Negative
RSI44.24Neutral
STOCH37.65Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JAGSNPHARM, the sentiment is Negative. The current price of 216.05 is below the 20-day moving average (MA) of 218.30, below the 50-day MA of 226.76, and above the 200-day MA of 207.11, indicating a neutral trend. The MACD of -2.72 indicates Negative momentum. The RSI at 44.24 is Neutral, neither overbought nor oversold. The STOCH value of 37.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JAGSNPHARM.

Jagsonpal Pharmaceuticals Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:JAGSNPHARM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:SYNCOMFIN:SYNCOMF79OutperformINR 19.08B22.34―0.49%0.44%48.60%
IN:JAGSNPHARMIN:JAGSNPHARM78OutperformINR 14.27B31.90―1.84%11.71%-26.92%
IN:VENUSREMIN:VENUSREM69NeutralINR 20.08B16.48―0.67%20.22%73.03%
IN:LINCOLNIN:LINCOLN67NeutralINR 10.46B10.87―0.35%14.25%21.11%
IN:SAKARIN:SAKAR57NeutralINR 22.88B54.28――47.99%117.99%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:INDSWFTLABIN:INDSWFTLAB51NeutralINR 31.41B37.29――66.39%-72.31%

* General Sector Average

Performance Comparison

0%100%200%300%IN:JAGSNPHARMIN:INDSWFTLABIN:LINCOLNIN:SAKARIN:SYNCOMFIN:VENUSREMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:JAGSNPHARM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:JAGSNPHARMJagsonpal Pharmaceuticals Ltd.216.059.424.56%
IN:INDSWFTLABInd-Swift Laboratories Ltd.361.25261.45261.97%
IN:LINCOLNLincoln Pharmaceuticals Ltd522.00-8.39-1.58%
IN:SAKARSakar Healthcare Ltd1042.40637.50157.45%
IN:SYNCOMFSyncom Formulation (India) Ltd.20.303.7922.97%
IN:VENUSREMVenus Remedies Limited1501.95949.71171.97%

Jagsonpal Pharmaceuticals Ltd. Corporate Events

Jagsonpal Pharma Sets Virtual AGM and Dividend Record Date for September 2026

Aug 27, 2026

Jagsonpal Pharmaceuticals Limited has scheduled its 47th Annual General Meeting for September 18, 2026, to be conducted via video conferencing and other audio-visual means in line with regulatory guidance. The company has circulated the AGM notice an...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026